View : 284 Download: 0

Heterologous Expression of Human SLC1A5v2 as a Functional Glutamine Transporter in Escherichia coli

Title
Heterologous Expression of Human SLC1A5v2 as a Functional Glutamine Transporter in Escherichia coli
Authors
Young Kim E.Park J.W.Kim O.B.
Ewha Authors
김옥빈
SCOPUS Author ID
김옥빈scopus
Issue Date
2023
Journal Title
Microbiology and Biotechnology Letters
ISSN
1598-642XJCR Link
Citation
Microbiology and Biotechnology Letters vol. 51, no. 1, pp. 37 - 42
Keywords
Escherichia coliglutamine transporterHeterologous expressionhuman SCL1A5v2
Publisher
Korean Society for Microbiolog and Biotechnology
Indexed
SCOPUS; KCI scopus
Document Type
Article
Abstract
Neutral and non-essential amino acid, glutamine (Gln), plays an essential role in supplying nitrogen to all the amino acids and nucleotides in the mammalian body. Gln is also the most important carbon source that provides intermediates for gluconeogenesis and fatty acid synthesis and supplements the tricarboxylic acid cycle in fast-growing cancer cells. Among the known 14 Gln transporter genes, soluted carrier family 1 member 5 (SLC1A5) has been reported to be closely associated with cancer cell growth. Three variants (v1, v2, and v3) have been derived from SLC1A5. Here, we established a heterologous gene expression system for the active form of human SLC1A5 variant-2 (hSLC1A5v2) in Escherichia coli. v2 is the smallest variant that has not yet been studied. Four expression systems were investigated: pBAD, pCold, pET, and pQE. We also addressed the problem of codon usage bias. Although pCold and pET overexpressed hSLC1A5v2 in E. coli, they were functionally inactive. hSLC1A5v2 using the pBAD system was able to catalyze the successful transport of Gln, even if it was not highly expressed. Initial activity of hSLC1A5v2 for [14C] Gln uptake in E. coli reached up to 6.73 μmole min-1 gDW-1 when the cell was induced with 80 mM L-arabinose. In this study, we demonstrated a heterologous expression system for the human membrane protein, SLC1A5, in E. coli. Our results can be used for the functional comparison of SLC1A5 variants (v1, v2, and v3) in future studies, to facilitae the developement of SLC1A5 inhibitors as effective anticancer drugs. © 2023, The Korean Society for Microbiology and Biotechnology.
DOI
10.48022/mbl.2301.01011
Appears in Collections:
자연과학대학 > 생명과학전공 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE